ADMA Biologics Inc. closed an underwritten offering of 12,937,500 common shares at $4 apiece to raise about $51.8 million in gross proceeds.

The Ramsey, N.J.-based company said the offering's underwriters fully exercised their option to buy 1,687,500 common shares at the offering price. Jefferies LLC and Raymond James & Associates Inc. were the joint book-running managers, while Oppenheimer & Co. Inc. was the lead manager for the offering.

ADMA plans to use the net proceeds for Asceniv's planned commercial launch during the second half of 2019 and for Bivigam's commercial relaunch.

Asceniv and Bivigam are used to treat primary humoral immunodeficiency disease, a group of disorders involving a compromised or incomplete immune system.

The funds will also be used to expand capacity at the company's Boca Raton, Fla., facility and grow its plasma collection facility network; to procure raw materials to manufacture Asceniv and Bivigam; and for general corporate purposes and other capital expenditures.